Todays trends might include catering more to consumers seeking healthier, protein-rich diets, or even investing in emerging technology (such as synthetic protein production) to maintain margins
The FDA has flagged safety risks for several compounded peptides, citing immunogenicity concerns and impurity questions, plus limited safety information for the proposed uses
A typical semaglutide titration: Weeks 1-4: 0.25mg once weekly Weeks 5-8: 0.5mg once weekly Weeks 9-12: 1.0mg once weekly Weeks 13-16: 1.7mg once weekly Week 17 onward: 2.4mg once weekly (maximum maintenance dose) A typical tirzepatide titration: Weeks 1-4: 2.5mg once weekly Weeks 5-8: 5.0mg once weekly Weeks 9-12: 7.5mg once weekly Weeks 13-16: 10mg once weekly Week 17 onward: 12.5-15mg once weekly (if needed) Some researchers find their optimal dose well below the maximum
GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide sit at different points on the price map, and the trial programs behind them, STEP (semaglutide, NEJM 2021) and SURMOUNT (tirzepatide, NEJM 2022), describe the compounds rather than any pricing tier
